Since the passage of the Biosimilar User Fee Act (BsUFA) in 2012, user fees have played an important role in expediting the process for the review of biosimilar products. BsUFA must be reauthorized every five years, and in August 2017, the President signed into law the Food and Drug Administration Reauthorization Act (FDARA), that includes the reauthorization of BsUFA through fiscal year 2022. To provide a snapshot of how FDA is meeting its commitments, the following table provides a listing of completed deliverables required under BsUFA. This table represents the original deliverables that FDA produced to meet its commitments, but it does not necessarily include more recent versions that may have posted after the deliverables were met.
Please note the summary table does not include deliverables intended for internal use, including:
- Updates to internal policies and procedures,
- Program updates or pilot programs,
- Staff training requirements and
- Interim milestones (e.g. Federal Register notices).
For more detailed information regarding BsUFA performance progress, please see the BsUFA Performance Reports page.
|Deliverable Title||Type||Description||Reference||Date Published|
|Best Practices for Communication Between IND Sponsors and FDA During Drug Development||Final Guidance||Updated guidance on best practices for communication between IND sponsors and FDA during drug development.||Meeting Management Goals||12/29/2017|
|BsUFA Quarterly Hiring Updates||Website Posting / Update||Quarterly hiring data to provide updates on the status of BsUFA-hired FTEs.||Set Clear Goals for Human Drug Review Program Hiring||Last Updated: 5/9/2019|
|Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product||Final Guidance||Publish final guidance on the clinical pharmacology data necessary to support a demonstration of biosimilarity.||Advancing Development of Biosimilar Biological Products Through Further Clarification of the 351(k) Regulatory Pathway||12/29/2016|
|Considerations in Demonstrating Interchangeability With a Reference Product||Final Guidance||Final guidance describing considerations for designating biosimilar biological products as interchangeable to a reference product.||Advancing Development of Biosimilar Biological Products Through Further Clarification of the 351(k) Regulatory Pathway||5/9/2019|
|Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations||Draft Guidance||Draft guidance describing the Agency's recommendations on the design and evaluation of comparative analytical studies.||Advancing Development of Biosimilar Biological Products Through Further Clarification of the 351(k) Regulatory Pathway||5/21/2019|
|Five-Year Financial Plan Fiscal Years 2018-2019-2020-2021-2022, 2018 Version, for BsUFA||Report||FDA's initial five-year financial plan which will be updated annually.||Financial Transparency and Efficiency||3/29/2018|
|Five-Year Financial Plan Fiscal Years 2018-2019-2020-2021-2022, 2019 Update, for BsUFA||Report||2019 update to FDA's five-year financial plan.||Financial Transparency and Efficiency||5/31/2019|
|Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products||Draft Guidance||Revised draft guidance on formal meetings between FDA and sponsors.||Meeting Management Goals||6/5/2018|
|FY2018 Human Drug User Fees Financial Management Evaluation||Public Report||Evaluation of PDUFA, BSUFA, and GDUFA program resource management during FY 2018.||Enhancing Management of User Fee Resources||5/22/2019|
|Good Review Management Principles and Practices for New Drug Applications and Biologics License Applications||Draft Guidance||Revised draft guidance on good review management principles and practices.||First Cycle Review Management||9/25/2018|
|Labeling for Biosimilar Products||Final Guidance||Publish final guidance on the labeling for biosimilar products.||7/19/2018|
|New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 2)||Draft Guidance||Publish draft guidance on the processes and considerations related to post-approval manufacturing changes for biosimilar biological products.||12/11/2018|
|Nonproprietary Naming of Biological Products||Final Guidance||Publish final guidance on the nonproprietary naming of biological products.||1/12/2017|
|Resource Capacity Planning & Modernized Time Reporting Implementation Plan||Implementation Plan||Implementation plan for FDA's approach to resource capacity planning and modernized time reporting.||Resource Capacity Planning and Modernized Time Reporting||3/30/2018|
|Statistical Approaches to Evaluate Analytical Similarity||Draft Guidance||Publish draft guidance on the evaluation of analytical similarity for biosimilar products.||Draft: 09/22/2017 Withdrawn: 6/21/2018|